Remove Biosimilars Remove Compounding Remove Magazine
article thumbnail

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

These closures, compounded by the decline of independent pharmacies, create a critical gap in care. R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

article thumbnail

Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug

Pharmaceutical Technology

Robert Barrie June 24, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Compounded GLP-1RA medication has become a key revenue driver for Hims & Hers’ telehealth platform. Hims & Hers’ revenue has been soaring on the back of its compounded glucagon-like peptide-1 receptor agonist (GLP-1RA) sales.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Why can’t the US figure out weight loss drug prices?

Pharmaceutical Technology

Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now? Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 receptor agonists (GLP-1RA), due to the emergence of compounded alternatives in the past few years.

article thumbnail

5th Oligonucleotides for CNS Summit

pharmaphorum

R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems. R&D Deep Dive: Research and Development 2025 Every breakthrough in medicine, every new treatment that changes lives, starts with research.

article thumbnail

Myasthenia gravis market to reach $10.3bn across 7MM by 2034

Pharmaceutical Technology

The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the US) is poised to grow at a compound annual growth rate of 5.3% Generic erosion and the entry of biosimilars are expected to be particularly significant in the US MG market. billion in 2024 to $10.3

article thumbnail

Three strategies for managing loss of exclusivity successfully

pharmaphorum

Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively. In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. They employed hundreds of new salespeople to detail doctors and hospitals, spent millions on TV and magazine ads and handed out masses of free samples.